# Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV

> **NCT04913272** · PHASE2 · SUSPENDED · sponsor: **Kibow Pharma** · enrollment: 630 (estimated)

## Conditions studied

- Chronic Kidney Disease stage4

## Interventions

- **DRUG:** US-APR2020
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04913272
- **Lead sponsor:** Kibow Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-06-24
- **Primary completion:** 2025-09
- **Final completion:** 2025-12
- **Target enrollment:** 630 (ESTIMATED)
- **Why stopped:** Logistics, company reorganization
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04913272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04913272, "Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04913272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*